Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1

Vinner, Lasse; Therrien, Dominic; Wee, Edd; Laursen, Inga; Hanke, Tomáš; Corbet, Sylvie; Fomsgaard, Anders

doi:10.1111/j.1600-0463.2006.apm_395.x

Cited by 14 publications

(14 citation statements)

References 37 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-Ab titers have been reported following heterologous prime-boost regimens using adenovirus-MVA or two adenoviral vectors of heterologous serotype (9,11). We previously reported in mice using vaccines against MSP1 that even higher Ab titers can be achieved by combining vectored vaccines with protein-in-adjuvant vaccines (31), similar to that seen in studies of HIV-1 vaccine candidates (32)(33)(34)(35)(36). The data in this study of two viral-vectored vaccines and protein-in-adjuvant vaccines in rhesus macaques agreed with the previous murine data, demonstrating that moderately high IgG was induced against both alleles of AMA1 by AdCh63-MVA immunization and that even higher titers could be induced by protein-in-adjuvant boosting.…”

Section: Discussionsupporting

confidence: 50%

Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines

Draper

Biswas

Spencer

et al. 2010

The Journal of Immunology

109

View full text Add to dashboard Cite

Protein-in-adjuvant formulations and viral-vectored vaccines encoding blood-stage malaria Ags have shown efficacy in rodent malaria models and in vitro assays against Plasmodium falciparum. Abs and CD4+ T cell responses are associated with protective efficacy against blood-stage malaria, whereas CD8+ T cells against some classical blood-stage Ags can also have a protective effect against liver-stage parasites. No subunit vaccine strategy alone has generated demonstrable high-level efficacy against blood-stage infection in clinical trials. The induction of high-level Ab responses, as well as potent T and B cell effector and memory populations, is likely to be essential to achieve immediate and sustained protective efficacy in humans. This study describes in detail the immunogenicity of vaccines against P. falciparum apical membrane Ag 1 in rhesus macaques (Macaca mulatta), including the chimpanzee adenovirus 63 (AdCh63), the poxvirus modified vaccinia virus Ankara (MVA), and protein vaccines formulated in Alhydrogel or CoVaccine HT adjuvants. AdCh63-MVA heterologous prime-boost immunization induces strong and long-lasting multifunctional CD8+ and CD4+ T cell responses that exhibit a central memory-like phenotype. Three-shot (AdCh63-MVA-protein) or two-shot (AdCh63-protein) regimens induce memory B cells and high-titer functional IgG responses that inhibit the growth of two divergent strains of P. falciparum in vitro. Prior immunization with adenoviral vectors of alternative human or simian serotype does not affect the immunogenicity of the AdCh63 apical membrane Ag 1 vaccine. These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans.

show abstract

Section: Discussionsupporting

confidence: 50%

Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines

Draper

Biswas

Spencer

et al. 2010

The Journal of Immunology

109

View full text Add to dashboard Cite

show abstract

“…The genes were synthesised and codon‐optimised for efficient expression in ferrets and humans by GeneArt (Regensburg, Germany) and cloned into a modified pWRG7079 (PowderJect, Middleton, Wisconsin, USA) DNA vaccine vector 12 . H3N2 genes were cloned into a clinical pKCMV standard expression vector kindly provided by Britta Wahren, Karolinska Institute, Sweden 13 .…”

Section: Methodsmentioning

confidence: 99%

“…The genes were synthesised and codon-optimised for efficient expression in ferrets and humans by GeneArt (Regensburg, Germany) and cloned into a modified pWRG7079 (PowderJect, Middleton, Wisconsin, USA) DNA vaccine vector. 12 H3N2 genes were cloned into a clinical pKCMV standard expression vector kindly provided by Britta Wahren, Karolinska Institute, Sweden. 13 Key elements in the expression vectors are the Kozak ribosomal signal sequence, a kanamycin resistance gene, strong constitutive CMV-IE promoter, polyadenylation signals and an intron A sequence in the pWRG7079 vector.…”

Section: Construction Of the Dna Vaccinesmentioning

confidence: 99%

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades

Bragstad

Martel

Thomsen

et al. 2010

Influenza and Other Respiratory Viruses

Self Cite

View full text Add to dashboard Cite

Please cite this paper as: Bragstad et al. (2010) Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross‐reactive immunity in ferrets against infection with viruses drifted for decades. Influenza and Other Respiratory Viruses 5(1), 13–23. Background Alternative influenza vaccines and vaccine production forms are needed as the conventional protein vaccines do not induce broad cross‐reactivity against drifted strains. Furthermore, fast vaccine production is especially important in a pandemic situation, and broader vaccine reactivity would diminish the need for frequent change in the vaccine formulations. Objective In this study, we compared the ability of pandemic influenza DNA vaccines to induce immunity against distantly related strains within a subtype with the immunity induced by conventional trivalent protein vaccines against homologous virus challenge. Methods Ferrets were immunised by particle‐mediated epidermal delivery (gene gun) with DNA vaccines based on the haemagglutinin (HA) and neuraminidase (NA) and/or the matrix (M) and nucleoprotein genes of the 1918 H1N1 Spanish influenza pandemic virus or the 1968 H3N2 Hong Kong influenza pandemic virus. The animals were challenged with contemporary H1N1 or H3N2 viruses. Results We demonstrated that DNA vaccines encoding proteins of the original 1918 H1N1 pandemic virus induced protective cross‐reactive immune responses in ferrets against infection with a 1947 H1N1 virus and a recent 1999 H1N1 virus. Similarly, a DNA vaccine, based on the HA and NA of the 1968 H3N2 pandemic virus, induced cross‐reactive immune responses against a recent 2005 H3N2 virus challenge. Conclusions DNA vaccines based on pandemic or recent seasonal influenza genes induced cross‐reactive immunity against contemporary virus challenge as good as or superior to contemporary conventional trivalent protein vaccines. This suggests a unique ability of influenza DNA to induce cross‐protective immunity against both contemporary and long‐time drifted viruses.

show abstract

“…The construction of BX08 gp140 (GenBank JX473289) plasmid used codons from highly expressed human genes as described earlier (46–48) and two other primary envs from Danish patients (ctl21 (JX473290) and ctl27 (JX473291) (49) were similarly codon optimized and cloned in the same expression plasmid with the key elements CMV IE promotor-enhancer, tPA secretion signal, and a bovine growth hormone poly A signal. Clones were verified by sequencing.…”

Section: Methodsmentioning

confidence: 99%

Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein

Uchtenhagen

Schiffner

Bowles

et al. 2014

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Our knowledge of the binding sites for neutralizing antibodies (NAbs) that recognize a broad range of HIV-1 strains (bNAb) has substantially increased in recent years. However, gaps remain in our understanding of how to focus B-cell responses to vulnerable conserved sites within the HIV-1 envelope glycoprotein (Env). Here we report an immunization strategy composed of a trivalent HIV-1 (clade B envs) DNA prime, followed by a SIVmac239 gp140 Env protein boost that aimed to focus the immune response to structurally conserved parts of the HIV-1 and SIV Envs. Heterologous NAb titres, primarily to tier 1 HIV-1 isolates, elicited during the trivalent HIV-1 env prime, were significantly increased by the SIVmac239 gp140 protein boost in rabbits. Epitope mapping of antibody binding reactivity revealed preferential recognition of the C1, C2, V2, V3 and V5 regions. These results provide a proof of concept that a distally related retroviral SIV Env protein boost can increase pre-existing NAb responses against HIV-1.

show abstract

Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1

Cited by 14 publications

References 37 publications

Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines

Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades

Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein

Contact Info

Product

Resources

About